Published in Viruses on April 14, 2014
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals | NCT00819390
Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs | NCT00099671
Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy | NCT00107549
Gene Transfer for HIV Using Autologous T Cells (Gene Transfer) | NCT01153646
Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS. Curr HIV/AIDS Rep (2015) 0.91
Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat Biotechnol (2016) 0.90
CRISPR-mediated Activation of Latent HIV-1 Expression. Mol Ther (2015) 0.88
HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads. J Virol (2016) 0.87
Genome editing strategies: potential tools for eradicating HIV-1/AIDS. J Neurovirol (2015) 0.87
RNA-Mediated Regulation of HMGA1 Function. Biomolecules (2015) 0.83
Promoter Targeting RNAs: Unexpected Contributors to the Control of HIV-1 Transcription. Mol Ther Nucleic Acids (2015) 0.81
Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1. Sci Rep (2015) 0.80
The microRNA miR-29a is associated with human immunodeficiency virus latency. Retrovirology (2014) 0.80
Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis. Immunology (2014) 0.77
Interaction of drugs of abuse and microRNA with HIV: a brief review. Front Microbiol (2015) 0.76
Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure. Front Immunol (2015) 0.76
HIV-1 Tat and Viral Latency: What We Can Learn from Naturally Occurring Sequence Variations. Front Microbiol (2017) 0.75
Achieving HIV-1 Control through RNA-Directed Gene Regulation. Genes (Basel) (2016) 0.75
RNA-Mediated Regulation of HMGA1 Function. Biomolecules (2015) 0.75
Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β. J Med Chem (2015) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
HIV-1 integration in the human genome favors active genes and local hotspots. Cell (2002) 12.60
Identification of host proteins required for HIV infection through a functional genomic screen. Science (2008) 12.44
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science (1984) 11.30
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell (1998) 10.14
Controlling the elongation phase of transcription with P-TEFb. Mol Cell (2006) 9.95
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45
T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis (2003) 8.00
A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res (2011) 7.93
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Acetylation and deacetylation of non-histone proteins. Gene (2005) 6.87
Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science (2001) 6.79
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med (2013) 6.63
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med (1995) 6.26
Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe (2008) 6.24
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med (2007) 6.01
Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2008) 5.94
The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell (2002) 5.84
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature (2001) 5.14
7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature (2001) 5.11
Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J (1996) 5.10
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA (1999) 4.98
Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J (2002) 4.91
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis (2008) 4.86
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med (2002) 4.73
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08
Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J (1993) 3.95
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
Macrophages as a source of HIV during opportunistic infections. Science (1997) 3.92
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med (2010) 3.81
The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J (2001) 3.80
Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol (2008) 3.74
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol (2000) 3.43
HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A (2008) 3.40
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (2010) 3.29
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation (2000) 3.22
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med (2012) 3.12
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med (1998) 3.11
Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci U S A (2007) 2.97
Effects of retroviruses on host genome function. Annu Rev Genet (2008) 2.96
Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest (2009) 2.92
Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol (2001) 2.91
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res (2002) 2.90
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Collagen deposition limits immune reconstitution in the gut. J Infect Dis (2008) 2.85
Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest (2002) 2.82
Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe (2008) 2.81
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol (2012) 2.80
Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. EMBO J (2004) 2.76
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75
Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J (2007) 2.74
The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity (1997) 2.66
HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe (2011) 2.59
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol (2002) 2.52